---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092213"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:18:07.014575+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors

## Summary
- Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.
- He will serve on the Audit Committee; receives $50k annual cash retainer plus $12.5k for committee role.
- Initial equity grant with $200k target fair value (split options/RSUs); prorated annual grant of $95,300.
- Future annual equity grants of $400k (half options, half RSUs) with quarterly vesting over one year.

## SEC filing metadata
- accession: 0001193125-26-092213
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/0001193125-26-092213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526092213/acad-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092213
- JSON: https://secwatch.observer/filing/0001193125-26-092213.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.